Senti Bio confirms recommended RP2D in Phase 1 study of SENTI-202

Senti Bio (SNTI)sciences announced it has confirmed the recommended Phase 2 dose, RP2D, in its Phase 1 study of SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer, CAR-NK, investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia, AML. The Phase 1 clinical trial of SENTI-202 is enrolling adult patients with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including AML, at multiple sites in the United States and Australia. The RP2D has been determined as Schedule I, Dose Level 2 administered on Days 0,7 and 14 of 28 Day Cycles following lymphodepleting chemotherapy and the trial is actively enrolling additional R/R AML patients into an expansion cohort at the RP2D.